Marín-Jiménez I, Peña A S
Department of Gastroenterology, Hospital General Universitario Gregorio Marañon, Madrid, Spain.
Rev Esp Enferm Dig. 2006 May;98(5):362-73. doi: 10.4321/s1130-01082006000500007.
In this review, we examined studies published on oral and topical formulations of budesonide (Entocort and Budenofalk, in Spain: Entocord and Intestifalk) for the treatment of ulcerative colitis. This glycocorticosteroid has a potent local action and an important first-pass liver metabolism. It has proven successful over the last years as a controlled-release formulation. It obtained results similar to prednisolone, without the latter s significant suppression of plasma cortisol. Many publications exist on the effects of oral budesonide for the treatment of Crohn s disease (CD). These have led to the registration of this drug for the treatment of CD. Studies on oral formulations of budesonide for the treatment of ulcerative colitis (UC) are scarce. After reviewing published evidence, we suggest the conduction of controlled trials for the treatment of UC to obtain evidence-based efficacy and safety results in order to benefit patients with this form of inflammatory bowel disease (IBD).
在本综述中，我们研究了已发表的关于布地奈德口服和局部用制剂（Entocort和Budenofalk，在西班牙为Entocord和Intestifalk）治疗溃疡性结肠炎的研究。这种糖皮质激素具有强大的局部作用和重要的首过肝代谢。在过去几年中，它作为一种控释制剂已被证明是成功的。它获得了与泼尼松龙相似的结果，且不会像后者那样显著抑制血浆皮质醇。关于口服布地奈德治疗克罗恩病（CD）的作用已有许多出版物。这些已促使该药物获批用于治疗CD。关于布地奈德口服制剂治疗溃疡性结肠炎（UC）的研究很少。在回顾已发表的证据后，我们建议开展治疗UC的对照试验，以获得基于证据的疗效和安全性结果，从而使这种炎症性肠病（IBD）患者受益。
